In the human brain, serotonin (5-HT) is synthesized from tryptophan by the enzyme tryptophan hydroxylase-2 (TPH2). Recently a rare variant (R441H) due to a single nucleotide change (G1463A) in the human tryptophan hydroxylase-2 gene (hTPH2) encoding the rate-limiting enzyme of neuronal serotonin synthesis, human tryptophan hydroxylase-2 (hTPH2), was demonstrated to dramatically reduce enzymatic activity. In vitro studies indicate that the ability of the mutant enzyme to synthesize serotonin (5-HT) is decreased 80% compared to the wild-type enzyme (Zhang et al 2005) . Interestingly, this rare genetic variant was found in 9/87 patients with unipolar major depression (UP) and only in 3/219 controls (all the affected individuals were Caucasians except for one control who was African American). Therefore, the R441H mutation could represent an important risk factor for UP. Given the predominant role of hTPH2 in brain serotonergic neurons (Walther et al 2003; Patel et al 2004) , and the large number of studies suggesting a dysfunction of the 5-HT system in many psychiatric conditions, we determined the incidence (or allelic frequency) of this variant in independent cohorts of patients with UP and other neuropsychiatric disorders.
Background: It was recently reported that a rare functional variant, R441H, in the human tryptophan hydroxylase-2 gene (hTPH2) could represent an important risk factor for unipolar major depression (UP) since it was originally found in 10% of UP patients (vs. 1.4% in controls).

Methods: We explored the occurrence of this variation in patients with affective disorders (n=646),
autism spectrum disorders (n=224) and OCD (n=201) , in healthy volunteers with no psychiatric disorders (n=246), and in an ethnic panel of control individuals from North Africa, India, China and Sweden (n=277) . In the human brain, serotonin (5-HT) is synthesized from tryptophan by the enzyme tryptophan hydroxylase-2 (TPH2). Recently a rare variant (R441H) due to a single nucleotide change (G1463A) in the human tryptophan hydroxylase-2 gene (hTPH2) encoding the rate-limiting enzyme of neuronal serotonin synthesis, human tryptophan hydroxylase-2 (hTPH2), was demonstrated to dramatically reduce enzymatic activity. In vitro studies indicate that the ability of the mutant enzyme to synthesize serotonin (5-HT) is decreased 80% compared to the wild-type enzyme (Zhang et al 2005) . Interestingly, this rare genetic variant was found in 9/87 patients with unipolar major depression (UP) and only in 3/219 controls (all the affected individuals were Caucasians except for one control who was African American). Therefore, the R441H mutation could represent an important risk factor for UP. Given the predominant role of hTPH2 in brain serotonergic neurons (Walther et al 2003; Patel et al 2004) , and the large number of studies suggesting a dysfunction of the 5-HT system in many psychiatric conditions, we determined the incidence (or allelic frequency) of this variant in independent cohorts of patients with UP and other neuropsychiatric disorders.
Results
Methods and Materials Subjects
We studied the G1463A polymorphism of the gene in a large sample of 1071 individuals with psychiatric disorders including UP (n=265), major depressive disorder (MDD) (n=297), bipolar disorder (BP) (n=84), obsessive compulsive disorder (OCD) (n=201), autism spectrum disorders 
Genotyping procedures
The G1463A SNP was analyzed using three different methods: with amplification refractory mutation system (ARMS)-PCR as described by Zhang et al (2005) , with PCR-RFLP or by sequencing.
For ARMS-PCR and PCR-RFLP, the PCR was done with the same external primers with Eurobio Taq polymerase, the PCR product was digested with 5 U of Fok I (Biolabs, Bioconcept, Basel-CH) during 5 hours at 37°C and the final product was run on a clearose gel (Elchrom). For sequencing, primers for the PCR were located in intron 9 (5'-CTGTAGGATTACCGAGCTATC-3') and intron 11 (5'-CGTCGTCAAGTCAGTTACAGT-3').
Results
We did not observe the 1463A allele in any of the individuals tested (Table 1 ). All the individuals were 1463G homozygous. Genotyping procedures were robust, since we were able to detect the mutation in genomic DNA from 1463A homozygous and heterozygous individuals obtained from Dr.
Caron. The frequency of the 1463A allele in UP reported by Zhang et al. (2005) is 6.89%; therefore we expected to observe about 36 1463A alleles in our sample of 265 UP patients (530 chromosomes).
For bipolar patients we confirmed the absence of the 1463A allele (Zhang et al 2005) . In the original paper, eleven individuals with the 1463A allele were of Caucasian origin and one was an African American. To explore the possibility that this rare variation is more frequent in other genetic backgrounds, we screened an ethnic panel of 277 control subjects from North Africa (n=62), SubSaharan Africa (n=48), India (n=42), China (n=54) and Sweden (n=71). We could not detect the 1463A allele in any of these individuals. In total, we failed to detect the 1463A polymorphism in 3188 chromosomes.
HAL author manuscript inserm-00124742, version 1 R. Delorme et al 4
Discussion
Compared to the original report (Zhang et al 2005) , the absence of the hTPH2 mutation in our study could not be solely explained by a difference in ethnicity since both study groups consisted predominantly of Caucasian individuals. It is also unlikely that diagnosis and sex-ratio could explain the apparent contradictory findings. One obvious difference between the individuals carrying the hTPH2 1463A allele in the study by Zhang et al (2005) and those described here is the age of the patients. In the report of Zhang et al UP patients were 60 years of age or older, whereas those in our study had a mean age at interview of 39.2 ± 13.9 years. However, this difference remains difficult to interpret, since no information on the age at onset of UP in the Zhang et al cohort is given.
In conclusion, we were unable to replicate the findings of Zhang et al (2005) . In addition, a recent study that systematically sequenced hTPH2 exons in subjects with autism and controls did not observe the G1463A variation (Coon et al 2005) . One reason for the discrepancy could be a sub- was not validated by sequencing analysis. Thus, a possible contamination of the subject samples by the cloning vector can not be excluded. Nevertheless, it remains possible that the G1463A hTPH2 variation is associated with a yet unknown UP-associated trait and/or an older age at onset. Further screening is warranted to address this open question.
